An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)

Bristol Myers Squibb

Description

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Citations (0)

Mentions (0)

Metrics

Dataset Index

0.3

FAIR Score

54%

Citations

0

Mentions

0

Metrics Over Time

Publication Details

DOI

Publisher

Vivli

License

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Assigned Domain

Subfield

Oncology

Field

Medicine

Domain

Health Sciences

Confidence Score

45%

Source

Scholar Data Model

Keywords

Conditions: Advanced MelanomaConditions: Metastatic MelanomaInterventions: NivolumabInterventions: Ipilimumab

Normalization Factors

FT

65.38

CTw

1.00

MTw

1.00